<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446325</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0236</org_study_id>
    <nct_id>NCT04446325</nct_id>
  </id_info>
  <brief_title>Venous Disease Thromboembolic and Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>TESLA</acronym>
  <official_title>Venous Disease Thromboembolic and Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thrombo-embolic (VTE) rates could be high in patients with amyotrophic lateral
      sclerosis (ALS). Indeed, the rate of VTE in this specific population could be 7-fold higher
      in this population. Predictiv factors of VTE in patients with ALS are mobility reduction and
      neurological paralysis. However, to our knowledge, medical littérature is poor concerning VTE
      and ALS association.

      Our first aim is to define annual rate of VTE in ALS population.Then we aim to identify
      predictiv factors of VTE in this specific population. The studied population is Brest
      universitary hospital cohort of ALS patient included between 2000 and 2019.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>venous thrombo-embolic eventsrate per year in amyotrophic lateral sclerosis patients followed between 2000 and 2019 in Brest universitary hospital</measure>
    <time_frame>19 years</time_frame>
    <description>pulmonary embolism and deep venous thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictiv factors of venous thrombo-embolism events in amyotrophic lateral sclerosis population followed in Brest universitary hospital between 2000 and 2019</measure>
    <time_frame>19 years</time_frame>
    <description>immobilization, impairment of respiratory function,, mecanical ventilation, denutrition, artificial nutrition</description>
  </secondary_outcome>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Lateral Amyotrophic Sclerosis</condition>
  <condition>Venous Thrombo-embolic Desease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with amyotrophic lateral sclerosis defined by revised El Escorial score criteria
        followed in competence centre of brest universitary hospital during 2000 to 2019
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with amyotrophic lateral sclerosis defined by revised El Escorial score
             criteria followed in competence centre of Brest Universitary Hospital during 2000 to
             2019

        Exclusion Criteria:

          -  no consent

          -  other neuro-degenerativ diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cécile DR TROMEUR, MD-PHD</last_name>
    <phone>+33662253807</phone>
    <email>cecile.tromeur@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>steeve DP Genestet, MD</last_name>
    <email>steeve.genestet@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile TROMEUR</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lateral amyotrophic sclerosis</keyword>
  <keyword>venous thrombo-embolic desase</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>deep venous thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

